Update and optimization of active surveillance in prostate cancer in 2021.
CONCLUSIONS: Controversial indications such as the inclusion of patients from intermediate-risk groups, or the transition to active treatment due to exclusive progression in tumor volume, should be further optimized. It is possible that the future competition of tissue biomarkers, the refinement of objective parameters of mpMRI and the validation of PSA kinetics calculators may sub-stratify risk groups.
PMID: 33070989 [PubMed - as supplied by publisher]
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Rubio-Briones J, Pastor Navarro B, Esteban EscaƱo LM, Borque Fernando A Tags: Actas Urol Esp Source Type: research
More News: Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | MRI Scan | Pathology | Prostate Cancer | Urology & Nephrology